Key result
Serum Angptl2 levels were significantly associated with liver fibrosis stages (P=0.02), and combining Angptl2 with FIB-4 or APRI distinguished significant fibrosis with an AUC of 92.5%.
Why the study?
Prognosis and management of chronic HBV depend on liver fibrosis, and the predictive value of the inflammatory and tissue-remodeling factor Angptl2 across different fibrosis stages needed exploration.
Does serum Angptl2 level accurately predict liver fibrosis stages in patients with chronic HBV infection?
Observational (n=80)
Does serum Angptl2 level accurately predict liver fibrosis stages in patients with chronic HBV infection?
Effect estimate: AUC 70.2%
p-value: p=0.02
Serum Angptl2 combined with FIB-4 or APRI shows high diagnostic accuracy for identifying significant liver fibrosis in chronic HBV patients.
Angptl2 was associated with fibrosis stage in chronic HBV; leaves open its incremental value over established noninvasive markers.
Background/aim: Hepatitis B virus (HBV) infection is the leading cause of liver fibrosis (LF). The prognosis and management of patients with chronic hepatitis B virus depend on the amount and progression of liver fibrosis. Angiopoietin-like protein 2 (Angptl2) is not only a chronic inflammatory mediator, but also a tissue-remodeling factor. The aim of this study is to explore the predictive value of Angptl2 in different fibrosis stages in patients chronically infected with HBV. Materials and methods: Eighty patients with chronic HBV infection undergoing Fibroscan were included. Serum concentrations of Angptl2 were detected using a commercial ELISA kit. Results: Angptl2 levels were significantly associated with liver fibrosis stages (P = 0.02). The area under the curve (AUC) of Angptl2 for distinguishing patients who showed significant fibrosis (F2–F4) was70.2%. Angptl2 with fibrosis-4 (FIB-4) and Angptl2 with AST/platelets ratio (APRI) performed best with an AUC of 92.5%. Conclusion: In patients with chronic HBV infection, Angptl2 level represents a potential biomarker independently associated with fibrosis stages. The combination of Angptl2 with FIB-4 or Angptl2 with APRI performed better than the existing models for diagnosing significant fibrosis.
No takes yet. Share an insight, caveat, or question.
Serag et al. (2019) conducted an observational in Chronic hepatitis B virus infection (n=80). Angptl2 (Angiopoietin-like protein 2) levels was evaluated on Distinguishing patients who showed significant fibrosis (F2-F4) (AUC 70.2%, p=0.02). Serum Angptl2 levels were significantly associated with liver fibrosis stages (P=0.02), and combining Angptl2 with FIB-4 or APRI distinguished significant fibrosis with an AUC of 92.5%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: